Page last updated: 2024-12-08

ly 311727

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LY 311727: a potent & selective inhibitor of human non-pancreatic secretory phospholipase A2; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID155922
CHEMBL ID146186
SCHEMBL ID7965980
MeSH IDM0251608

Synonyms (28)

Synonym
phosphonic acid, [3-[[3-(2-amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-5-yl]oxy]-propyl]-
ly311727
3-[3-(2-amino-2-oxo-ethyl)-1-benzyl-2-ethyl-indol-5-yl]oxypropylphosphonic acid
ly 311727
164083-84-5
chembl146186 ,
(3-{[1-benzyl-3-(carbamoylmethyl)-2-ethyl-1h-indol-5-yl]oxy}propyl)phosphonic acid
bdbm23771
ly-311727
3-[3-(2-amino-2-oxoethyl)-1-benzyl-2-ethylindol-5-yl]oxypropylphosphonic acid
u8d ,
(3-{[3-(2-amino-2-oxoethyl)-1-benzyl-2-ethyl-1h-indol-5-yl]oxy}propyl)phosphonic acid
phosphonic acid, (3-((3-(2-amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-5-yl)oxy)propyl)-
SCHEMBL7965980
OPWQYOUZRHDKBR-UHFFFAOYSA-N ,
[3-[[3-(2-amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-5-yl]oxy]propyl]phosphonic acid
ly 311727|[3-[[3-(2-amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-5-yl]oxy]propyl]-phosphonic acid
AKOS024457722
DTXSID80167706
ly311727, >=98% (hplc), powder
J-010111
NCGC00370857-01
[3-[[3-(2-amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-5-yl]oxy]propyl]-phosphonic acid
(3-((3-(2-amino-2-oxoethyl)-1-benzyl-2-ethyl-1h-indol-5-yl)oxy)propyl)phosphonic acid
Q27466824
phosphonic acid, p-[3-[[3-(2-amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-5-yl]oxy]propyl]-
HY-107393
CS-0028363

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency37.90830.01237.983543.2770AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phospholipase A2, major isoenzymeSus scrofa (pig)IC50 (µMol)6.49400.04804.12088.0000AID1798358; AID280824; AID315576; AID479418
Phospholipase A2, membrane associatedHomo sapiens (human)IC50 (µMol)17.06290.00301.08118.0000AID158934; AID158961; AID159096; AID1798358; AID280825; AID315575; AID479417
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
signal transductioncGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cellular response to macrophage colony-stimulating factor stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
negative regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
positive regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
GMP catabolic processcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cGMP catabolic processcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
positive regulation of inflammatory responsecGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
establishment of endothelial barriercGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cellular response to mechanical stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cellular response to cGMPcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cellular response to granulocyte macrophage colony-stimulating factor stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
phospholipid metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
inflammatory responsePhospholipase A2, membrane associatedHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPhospholipase A2, membrane associatedHomo sapiens (human)
lipid catabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
killing of cells of another organismPhospholipase A2, membrane associatedHomo sapiens (human)
low-density lipoprotein particle remodelingPhospholipase A2, membrane associatedHomo sapiens (human)
intestinal stem cell homeostasisPhospholipase A2, membrane associatedHomo sapiens (human)
phosphatidylethanolamine metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
phosphatidylcholine metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
phosphatidic acid metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
arachidonic acid secretionPhospholipase A2, membrane associatedHomo sapiens (human)
positive regulation of inflammatory responsePhospholipase A2, membrane associatedHomo sapiens (human)
defense response to Gram-positive bacteriumPhospholipase A2, membrane associatedHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePhospholipase A2, membrane associatedHomo sapiens (human)
regulation of neutrophil activationPhospholipase A2, membrane associatedHomo sapiens (human)
negative regulation of T cell proliferationPhospholipase A2, membrane associatedHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
3',5'-cyclic-AMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cGMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
metal ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
phospholipase A2 activityPhospholipase A2, membrane associatedHomo sapiens (human)
phospholipid bindingPhospholipase A2, membrane associatedHomo sapiens (human)
calcium-dependent phospholipase A2 activityPhospholipase A2, membrane associatedHomo sapiens (human)
calcium ion bindingPhospholipase A2, membrane associatedHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
endoplasmic reticulumcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
Golgi apparatuscGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
presynaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
extracellular regionPhospholipase A2, membrane associatedHomo sapiens (human)
extracellular spacePhospholipase A2, membrane associatedHomo sapiens (human)
mitochondrial outer membranePhospholipase A2, membrane associatedHomo sapiens (human)
endoplasmic reticulumPhospholipase A2, membrane associatedHomo sapiens (human)
endoplasmic reticulum membranePhospholipase A2, membrane associatedHomo sapiens (human)
plasma membranePhospholipase A2, membrane associatedHomo sapiens (human)
secretory granulePhospholipase A2, membrane associatedHomo sapiens (human)
perinuclear region of cytoplasmPhospholipase A2, membrane associatedHomo sapiens (human)
extracellular exosomePhospholipase A2, membrane associatedHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID479417Inhibition of human recombinant group 2A phospholipase A2 by fluorimetric assay2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Design of new potent and selective secretory phospholipase A(2) inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/di
AID286327Inhibition of NF-kappaB DNA binding in LPS-stimulated mouse RAW264.7 cells2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prosta
AID387839Inhibition of human synovial recombinant group 2A sPLA2 at 10 uM2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Development of a second generation of inhibitors of microsomal prostaglandin E synthase 1 expression bearing the gamma-hydroxybutenolide scaffold.
AID387840Inhibition of pig pancreas group 1B sPLA2 at 10 uM2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Development of a second generation of inhibitors of microsomal prostaglandin E synthase 1 expression bearing the gamma-hydroxybutenolide scaffold.
AID1904100Inhibition of AFM induced autophagy in human LNCaP cells assessed as suppression of autophagosome by DAP green staining based assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery and Structure-Based Optimization of Novel Atg4B Inhibitors for the Treatment of Castration-Resistant Prostate Cancer.
AID159096Inhibitory activity against porcine pancreatic Phospholipase A21996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality.
AID315576Inhibition of pig pancreatic PLA2 by fluorometric assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines.
AID158961Inhibitory activity against human pancreatic Phospholipase A21996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality.
AID286316Inhibition of pig sPLA2 at 10 uM2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prosta
AID1904099Inhibition of AFM induced autophagy in human LNCaP cells assessed as restoration of p62 expression at 5 uM by Western blot analysis2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery and Structure-Based Optimization of Novel Atg4B Inhibitors for the Treatment of Castration-Resistant Prostate Cancer.
AID286317Inhibition of human synovial recombinant sPLA2 at 10 uM2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prosta
AID280824Inhibition of pig group IB PLA2 by fluorimetric assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Inhibition of secreted phospholipase A2. 4-glycerol derivatives of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one with broad activities.
AID76956Effective dose of compound against contraction of Guinea pig lung tissue with arachidonic acid.1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality.
AID387841Inhibition of Naja naja venom group 1A sPLA2 at 10 uM2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Development of a second generation of inhibitors of microsomal prostaglandin E synthase 1 expression bearing the gamma-hydroxybutenolide scaffold.
AID286315Inhibition of Naja naja venom sPLA2 at 10 uM2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prosta
AID479418Inhibition of porcine group 1B phospholipase A2 by fluorimetric assay2010Bioorganic & medicinal chemistry, May-15, Volume: 18, Issue:10
Design of new potent and selective secretory phospholipase A(2) inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/di
AID77968Inhibitory activity against contraction of Guinea pig lung tissue induced by PLA2.1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality.
AID228954Mole fraction is the IC50 concentration divided by total lipid concentration1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality.
AID280825Inhibition of human group IIA PLA2 by fluorimetric assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Inhibition of secreted phospholipase A2. 4-glycerol derivatives of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one with broad activities.
AID1904095Inhibition of recombinant ATG4B (unknown origin) expressed in Escherichia coli BL21(DE3) pLysS cells at 10 uM using LC3-GST as substrate incubated for 3 hrs by coomassie brilliant blue staining based assay2022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Discovery and Structure-Based Optimization of Novel Atg4B Inhibitors for the Treatment of Castration-Resistant Prostate Cancer.
AID158934Inhibition of human non-pancreatic secretory phospholipase A2 (PLA2) in a chromogenic assay1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Indole inhibitors of human nonpancreatic secretory phospholipase A2. 2. Indole-3-acetamides with additional functionality.
AID387838Inhibition of bee venom group 3 sPLA2 at 10 uM2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Development of a second generation of inhibitors of microsomal prostaglandin E synthase 1 expression bearing the gamma-hydroxybutenolide scaffold.
AID286318Inhibition of bee venom sPLA2 at 10 uM2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prosta
AID315575Inhibition of human recombinant PLA2 by fluorometric assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines.
AID1798358Fluorimetric Assay from Article 10.1016/j.bmc.2007.10.077: \\Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)]2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (33.33)18.2507
2000's15 (45.45)29.6817
2010's4 (12.12)24.3611
2020's3 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.85 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.03%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (96.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]